Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $12.28 Million |
|---|---|
| Enterprise Value | $-7,547,458.00 |
| Earnings per Share | $-3.06 |
| Beta | 0.77 |
| Outstanding Shares | 5,411,334 |
| P/E Ratio | -0.35 |
|---|---|
| PEG | 0.36 |
| Price to Sales | - |
| Price to Book Ratio | 0.57 |
| Enterprise Value to Revenue | -5.14 |
| Enterprise Value to EBIT | 0.54 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 11.08%▼ 25.77% |
|---|---|
| Total Invested | $2.13M▼ 75.51% |
| Investors Holding | 10▼ 12.00% |
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals l...